Dutch immuno-oncology company Merus has appointed John Crowley its Chief Financial Officer. Former CFO Shelley Margetson has been elevated to Chief Operating Officer.
French cellular immunotherapy company TxCell has hired ex-Novartis Lab Head Li Zhou to lead its CAR-Treg programmes. Zhou was appointed Vice President Cell Engineering in October.
Norwegion immuno-oncology play Targovax has promoted Øystein Soug, previously the companys Chief Financial Officer, to the role of Chief Executive Officer. He succeeds Gunnar Gårdemyr, who has stepped down.
Finnish-Swedish biomaterial expert Stora Enso has appointed Annica Bresky as Executive Vice President, Consumer Board division and member of the Group Leadership Team. Bresky joins from Iggesund Paperboard AB, part of the Swedish Holmen Group, where she held the position of President and CEO.
Irish drug developer Icon plc has announced that, come March 2017, Steve Cutler will take over the leadership of the company. He succeeds Ciaran Murray, who will in turn transition to the role of Chairman of the Board.
Miquel A. Pericàs has taken over as general director of the Barcelona Institute of Science and Technology (BIST). The chemical engineer has been holding the position of director of the Institute of Chemical Research of Catalonia since 2000.
3P Biopharmaceuticals has hired Andrew Carver as its new Senior Head of Business Development. Carver joins 3P from UK-based CDMO Fujifilm Diosynth Biotechnology.
After being leaderless for over a year, EffRx has a new CEO. In October, EffRx announced that Lorenzo Bosisio has taken over the companys helm in July.
Swiss oncology expert Nouscom has appointed Marina Udier Blagovic as its Chief Operating Officer. The position has been newly created to drive all aspects of business operations and business development.
Cambridge-based drug discovery company Crescendo Biologics Ltd has named Theodora Harold its Chief Financial Officer. She has held this position in several early stage and growing biotechs.